BMIQ12
MCID: BDY015
MIFTS: 46

Body Mass Index Quantitative Trait Locus 12 (BMIQ12)

Categories: Bone diseases, Genetic diseases, Mental diseases, Metabolic diseases

Aliases & Classifications for Body Mass Index Quantitative Trait Locus 12

MalaCards integrated aliases for Body Mass Index Quantitative Trait Locus 12:

Name: Body Mass Index Quantitative Trait Locus 12 57 29 6 39
Obesity, Susceptibility to, Bmiq12 57 13
Obesity 57 70
Obesity, Susceptibility to 57
Obesity Bmiq12 57
Bmiq12 57

Classifications:



External Ids:

OMIM® 57 612362
UMLS 70 C0028754

Summaries for Body Mass Index Quantitative Trait Locus 12

MalaCards based summary : Body Mass Index Quantitative Trait Locus 12, also known as obesity, susceptibility to, bmiq12, is related to body mass index quantitative trait locus 11 and proprotein convertase 1/3 deficiency, and has symptoms including symptoms, high weight and obesity, metabolically benign. An important gene associated with Body Mass Index Quantitative Trait Locus 12 is PCSK1 (Proprotein Convertase Subtilisin/Kexin Type 1). The drugs Dalteparin and Cilostazol have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and breast.

More information from OMIM: 612362

Related Diseases for Body Mass Index Quantitative Trait Locus 12

Diseases in the Body Mass Index Quantitative Trait Locus 11 family:

Body Mass Index Quantitative Trait Locus 9 Body Mass Index Quantitative Trait Locus 8
Body Mass Index Quantitative Trait Locus 1 Body Mass Index Quantitative Trait Locus 2
Body Mass Index Quantitative Trait Locus 3 Body Mass Index Quantitative Trait Locus 4
Body Mass Index Quantitative Trait Locus 10 Body Mass Index Quantitative Trait Locus 7
Body Mass Index Quantitative Trait Locus 5 Body Mass Index Quantitative Trait Locus 6
Body Mass Index Quantitative Trait Locus 12 Body Mass Index Quantitative Trait Locus 13
Body Mass Index Quantitative Trait Locus 14 Body Mass Index Quantitative Trait Locus 15
Body Mass Index Quantitative Trait Locus 18 Body Mass Index Quantitative Trait Locus 19
Body Mass Index Quantitative Trait Locus 20

Diseases related to Body Mass Index Quantitative Trait Locus 12 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1938)
# Related Disease Score Top Affiliating Genes
1 body mass index quantitative trait locus 11 32.2 PCSK1 LOC101929710
2 proprotein convertase 1/3 deficiency 31.5 PCSK1 LOC101929710
3 syndromic obesity 30.9 PCSK1 LOC101929710
4 body mass index quantitative trait locus 19 11.9
5 leptin deficiency or dysfunction 11.9
6 body mass index quantitative trait locus 4 11.8
7 body mass index quantitative trait locus 9 11.8
8 body mass index quantitative trait locus 8 11.8
9 body mass index quantitative trait locus 7 11.8
10 body mass index quantitative trait locus 18 11.8
11 body mass index quantitative trait locus 14 11.8
12 body mass index quantitative trait locus 10 11.8
13 leptin receptor deficiency 11.5
14 cohen syndrome 11.5
15 obesity-hypoventilation syndrome 11.5
16 obesity, early-onset, with adrenal insufficiency and red hair 11.5
17 wilson-turner x-linked mental retardation syndrome 11.5
18 abdominal obesity-metabolic syndrome 3 11.5
19 mehmo syndrome 11.5
20 morbid obesity and spermatogenic failure 11.5
21 abdominal obesity-metabolic syndrome quantitative trait locus 2 11.5
22 abdominal obesity-metabolic syndrome 1 11.4
23 obesity, hyperphagia, and developmental delay 11.4
24 mental retardation, truncal obesity, retinal dystrophy, and micropenis syndrome 11.4
25 abdominal obesity-metabolic syndrome 4 11.4
26 hypothalamic obesity 11.4
27 spastic paraplegia, intellectual disability, nystagmus, and obesity 11.4
28 momo syndrome 11.4
29 retinal dystrophy and obesity 11.4
30 chung-jansen syndrome 11.4
31 chops syndrome 11.4
32 genetic obesity 11.3
33 wilms tumor, aniridia, genitourinary anomalies, mental retardation, and obesity syndrome 11.3
34 body mass index quantitative trait locus 20 11.3
35 fatty liver disease 11.3
36 non-alcoholic fatty liver disease 11.3
37 hydrocephalus obesity hypogonadism 11.3
38 ayazi syndrome 11.3
39 rohhad 11.2
40 coenzyme q10 deficiency, primary, 2 11.2
41 aniridia - ptosis - intellectual disability - familial obesity 11.2
42 type 2 diabetes mellitus 11.2
43 prader-willi syndrome 11.2
44 glucose intolerance 11.2
45 body mass index quantitative trait locus 1 11.2
46 polycystic ovary syndrome 11.2
47 eating disorder 11.2
48 alstrom syndrome 11.2
49 x-linked intellectual disability - short stature - obesity 11.2
50 man1b1-cdg 11.1

Graphical network of the top 20 diseases related to Body Mass Index Quantitative Trait Locus 12:



Diseases related to Body Mass Index Quantitative Trait Locus 12

Symptoms & Phenotypes for Body Mass Index Quantitative Trait Locus 12

Clinical features from OMIM®:

612362 (Updated 05-Apr-2021)

UMLS symptoms related to Body Mass Index Quantitative Trait Locus 12:


symptoms; high weight; obesity, metabolically benign; monogenic obesity

Drugs & Therapeutics for Body Mass Index Quantitative Trait Locus 12

Drugs for Body Mass Index Quantitative Trait Locus 12 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 954)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dalteparin Approved Phase 4 9005-49-6
2
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
3
Ticagrelor Approved Phase 4 274693-27-5 9871419
4
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
5
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
6
Indapamide Approved Phase 4 26807-65-8 3702
7
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
8
Linagliptin Approved Phase 4 668270-12-0 10096344
9
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
10
Metyrapone Approved, Investigational Phase 4 54-36-4 4174
11
Tolnaftate Approved, Investigational, Vet_approved Phase 4 2398-96-1 5510
12
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
13
Atorvastatin Approved Phase 4 134523-00-5 60823
14
Fenofibrate Approved Phase 4 49562-28-9 3339
15
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
16
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
17
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
18
Clarithromycin Approved Phase 4 81103-11-9 84029
19
Bismuth subsalicylate Approved, Vet_approved Phase 4 14882-18-9 53629521
20
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 2713 9552079
21
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585 135398745
22
Ziprasidone Approved Phase 4 146939-27-7 60854
23
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
24
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
25
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
26
Calcium carbonate Approved, Investigational Phase 4 471-34-1
27
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
28
Octreotide Approved, Investigational Phase 4 83150-76-9 6400441 383414
29
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
30
Meropenem Approved, Investigational Phase 4 119478-56-7, 96036-03-2 441130 64778
31 Orange Approved Phase 4
32
Magnesium oxide Approved Phase 4 1309-48-4 14792
33
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
34
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
35
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
36
Coal tar Approved Phase 4 8007-45-2
37
Repaglinide Approved, Investigational Phase 4 135062-02-1 65981
38
Losartan Approved Phase 4 114798-26-4 3961
39
Ofloxacin Approved Phase 4 82419-36-1 4583
40
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
41
Tedizolid Approved, Investigational Phase 4 856866-72-3
42
Tedizolid phosphate Approved Phase 4 856867-55-5
43
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
44
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
45
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
46
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
47
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643 439492
48
Doxorubicin Approved, Investigational Phase 4 23214-92-8 31703
49
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
50
Glyburide Approved Phase 4 10238-21-8 3488

Interventional clinical trials:

(show top 50) (show all 7845)
# Name Status NCT ID Phase Drugs
1 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
2 Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
3 Levonorgestrel-releasing Intrauterine Device Effects on Hemostatic and Arterial Function of Obese Women Unknown status NCT01320917 Phase 4
4 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
5 Vitamin D Concentrations and Their Effect on Glucose Metabolism in Pediatrics Unknown status NCT01386736 Phase 4 Vitamin D drops;Placebo drops
6 International, Multi Centre, Open, Prospective, Randomized Study: Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
7 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
8 Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2) Unknown status NCT02641301 Phase 4 Sustained release morphine sulfate, 30 mg
9 Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity Unknown status NCT02438020 Phase 4 Metformin
10 Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
11 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
12 Early Detection of Atherosclerosis in the Primary Care Setting: a Randomized Trial to Assess the Efficacy of a Novel Strategy in the Primary Prevention of Cardiovascular Diseases. Unknown status NCT00734123 Phase 4 Simvastatin or Atorvastatin;Enalapril;Aspirin or clopidogrel;Rimonabant
13 PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor Unknown status NCT02698618 Phase 4 Randomization
14 A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity. Unknown status NCT01864187 Phase 4 Dexmedetomidine
15 The Effect of Moxonidine and Regression of Early Target Organ Damage in Young Subjects With Abdominal Obesity and Hypertension: a Randomised, Double Blind, Active Comparator Clinical Trial Unknown status NCT01360710 Phase 4 Moxonidine;Irbesartan
16 Prevention and Control of Obesity in Primary School Children in Tehran Unknown status NCT02082080 Phase 4
17 Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B Unknown status NCT02759393 Phase 4 Dexlansoprazole;Lansoprazole
18 Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study Unknown status NCT02999841 Phase 4 Acarbose;Vildagliptin
19 The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02276235 Phase 4
20 The Effect of Probiotics on Obesity. Metabolic Endotoxemia and Inflammation Unknown status NCT03883685 Phase 4
21 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
22 Assessment of the Effect of Moxonidine and Diet on Cardiac, Renal and Endothelial Function in Young Subjects With Abdominal Obesity Unknown status NCT01180231 Phase 4 Moxonidine (Physiotens)
23 Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity Unknown status NCT01960205 Phase 4 Saxagliptin;saxagliptin;metformin
24 Laparoscopic Roux-en-Y Gastric Bypass vs. Laparoscopic BPD-Duodenal Switch for Superobesity (BMI > 50 kg/m2)- A Randomized Clinical Trial Unknown status NCT00327912 Phase 4
25 Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities Unknown status NCT02050477 Phase 4
26 Healthy Opportunities for Physical Activity and Nutrition (HOP'N) After-School Project Unknown status NCT01015599 Phase 4
27 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
28 Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery. Unknown status NCT02295150 Phase 4 Nadroparin
29 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Unknown status NCT02374632 Phase 4
30 Prospective Randomized Study of Effects of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
31 Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial Unknown status NCT02017314 Phase 4 Morphine
32 Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade Unknown status NCT02118844 Phase 4 rocuronium
33 Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia Unknown status NCT01805284 Phase 4 Linezolid
34 Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial Unknown status NCT01878994 Phase 4
35 Study of Metabolic Effects of EndoBarrier Versus Intragastric Balloon in Obese Patients With Type 2 Diabetes. Unknown status NCT01848795 Phase 4
36 The Need of Dosing Adjustment for Simvastatin in Obese Patients Post Bariatric Surgery- Laparoscopic Sleeve Gastrectomy (LSG) Unknown status NCT03571802 Phase 4 Simvastatin
37 The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects Unknown status NCT02372630 Phase 4 Linagliptin;Placebo
38 Retroclavicular Approach vs Infraclavicular Approach for Brachial Plexus Block in Obese Unknown status NCT02990702 Phase 4 Bupivacaine
39 Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients Unknown status NCT03361098 Phase 4 Dapagliflozin 10mg;Exenatide
40 What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone(BLOOD STUDY) Unknown status NCT02503943 Phase 4 "Liraglutide" and "Mitiglinide";"Metformin" and "Mitiglinide";"Mitiglinide"
41 Structured Exerise Training in Infertile Obese Patients Treated With Assisted Reproductive Techniques: a Randomized Controlled Trial Unknown status NCT01892111 Phase 4
42 Double-blind and Placebo-controlled Study on Intervention Effect of n-3 Fatty Acids on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Populations Unknown status NCT03708887 Phase 4 Low dose omega-3 fatty acid supplementation;High dose omega-3 fatty acid supplementation;Control drug
43 Oral Tramadol Versus Oral Celecoxib for Post-perineal Repair Analgesia After Spontaneous Vaginal Birth in Obese Women: A Randomised Controlled Trial Unknown status NCT03694873 Phase 4 Tramadol Hydrochloride;Celecoxib 200mg
44 Influence of the Aromatase Inhibitor Letrozole on Heart and Liver Function in Obese Men Unknown status NCT02097680 Phase 4 Letrozole;Placebo
45 HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial Unknown status NCT03476616 Phase 4 Eplerenone (-based therapy) arm;Valsartan (-based therapy) arm
46 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
47 Heparin Management for Cardiopulmonary Bypass in Cardiac Surgery: A Prospective, Comparative and Randomized Study Evaluating a Dosage Based on the Ideal Body Weight in Obese Patients Unknown status NCT02675647 Phase 4 Heparin, IV route, based on patients body weights (UI/kg);Protamin administration
48 The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome Unknown status NCT01620684 Phase 4 metyrapone;placebo
49 The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men Unknown status NCT03002675 Phase 4 Bydureon
50 Investigating Whether the Magnitude of Postoperative Inflammatory and Insulin Resistant Responses is Related to Body Composition and Physiological Function of Skeletal Muscle & Adipose Tissue Unknown status NCT01470534 Phase 4

Search NIH Clinical Center for Body Mass Index Quantitative Trait Locus 12

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Benzphetamine
Benzphetamine hydrochloride
Dexfenfluramine
Dexfenfluramine Hydrochloride
Diethylpropion
Diethylpropion Hydrochloride
Fenfluramine
Fenfluramine Hydrochloride
lorcaserin
lorcaserin hydrochloride
Mazindol
Methamphetamine
orlistat
phendimetrazine
PHENDIMETRAZINE HYDROCHLORIDE
phendimetrazine tartrate
Phenmetrazine
Phenmetrazine Hydrochloride
Phentermine
Phentermine Hydrochloride
PHENTERMINE RESIN
Phenylpropanolamine
Phenylpropanolamine Hydrochloride
sibutramine
SIBUTRAMINE HYDROCHLORIDE

Genetic Tests for Body Mass Index Quantitative Trait Locus 12

Genetic tests related to Body Mass Index Quantitative Trait Locus 12:

# Genetic test Affiliating Genes
1 Body Mass Index Quantitative Trait Locus 12 29 PCSK1

Anatomical Context for Body Mass Index Quantitative Trait Locus 12

MalaCards organs/tissues related to Body Mass Index Quantitative Trait Locus 12:

40
Liver, Endothelial, Breast, Ovary, Kidney, Skeletal Muscle, Bone

Publications for Body Mass Index Quantitative Trait Locus 12

Articles related to Body Mass Index Quantitative Trait Locus 12:

(show top 50) (show all 30005)
# Title Authors PMID Year
1
Common nonsynonymous variants in PCSK1 confer risk of obesity. 6 57
18604207 2008
2
A genome-wide scan for quantitative trait loci linked to obesity phenotypes among West Africans. 57
15611782 2005
3
Genome-wide linkage analysis for severe obesity in french caucasians finds significant susceptibility locus on chromosome 19q. 57
15220211 2004
4
Genomic scan for genes affecting body composition before and after training in Caucasians from HERITAGE. 57
11299268 2001
5
A genome-wide scan for human obesity genes reveals a major susceptibility locus on chromosome 10. 57
9806554 1998
6
The effect of body mass index on the development of acute kidney injury and mortality in intensive care unit: is obesity paradox valid? 61
33745415 2021
7
Drosophila as a useful model for understanding the evolutionary physiology of obesity resistance and metabolic thrift. 61
33704003 2021
8
Estimating the prevalence of overweight and obesity in Nigeria in 2020: a systematic review and meta-analysis. 61
33783281 2021
9
Blood pro-oxidant/antioxidant balance in young men with class II obesity after 20 sessions of whole body cryostimulation: a preliminary study. 61
33560197 2021
10
Childhood exposure to parental smoking and life-course overweight and central obesity. 61
33305629 2021
11
Association between rs174537 FADS1 polymorphism and immune cell profiles in abdominal and femoral subcutaneous adipose tissue: an exploratory study in adults with obesity. 61
33595419 2021
12
Brown and beige adipose tissue: a novel therapeutic strategy for obesity and type 2 diabetes mellitus. 61
33403891 2021
13
Swertiamarin supplementation prevents obesity-related chronic inflammation and insulin resistance in mice fed a high-fat diet. 61
33794740 2021
14
The role and research progress of the balance and interaction between regulatory T cells and other immune cells in obesity with insulin resistance. 61
33472506 2021
15
Attitudes, behaviours and strategies towards obesity patients in primary care: A qualitative interview study with general practitioners in Germany. 61
33749477 2021
16
Development of novel functional snacks containing nano-encapsulated resveratrol with anti-diabetic, anti-obesity and antioxidant properties. 61
33691210 2021
17
Ambient air pollution and obesity in school-aged children and adolescents: A multicenter study in China. 61
33524680 2021
18
Prenatal exposure to persistent organic pollutants and markers of obesity and cardiometabolic risk in Spanish adolescents. 61
33711537 2021
19
Dysfunction of perivascular adipose tissue in mesenteric artery is restored by aerobic exercise in high-fat diet induced obesity. 61
32893373 2021
20
Obesity aggravates COVID-19: An updated systematic review and meta-analysis. 61
33200825 2021
21
Potential Ameliorative Effects of Chromium Supplementation on Glucose Metabolism, Obesity, and Genomic Stability in Prediabetic Rat Model. 61
32710349 2021
22
Adults' attitudes toward children, adolescents, and adults who are obese and tax-funded programs to combat obesity. 61
33198607 2021
23
Low-Molecular-Weight Heparin and Fondaparinux Use in Pediatric Patients With Obesity. 61
32864984 2021
24
A haplotype of the ANGPTL3 gene is associated with CVD risk, diabetes mellitus, hypertension, obesity, metabolic syndrome, and dyslipidemia. 61
33636293 2021
25
Association and potential mediators between socioeconomic status and childhood overweight/obesity. 61
33617865 2021
26
Dyspnea during exercise and voluntary hyperpnea in women with obesity. 61
33581294 2021
27
Index of Nutritional Quality (INQ) and the Risk of Obesity in Male Adolescents: a Case-Control Study. 61
32895892 2021
28
Danthron ameliorates obesity and MAFLD through activating the interplay between PPARα/RXRα heterodimer and adiponectin receptor 2. 61
33581653 2021
29
Obesity and aging: Molecular mechanisms and therapeutic approaches. 61
33556548 2021
30
Association of infant diet with subsequent obesity at 2-5 years among children exposed to gestational diabetes: the SWIFT study. 61
33495846 2021
31
Obesity and incident gastrointestinal cancers: overall body size or central obesity measures, which factor matters? 61
33783379 2021
32
Sex differences in markers of metabolic syndrome and adipose tissue inflammation in obesity-prone, Osborne-Mendel and obesity-resistant, S5B/Pl rats. 61
33662430 2021
33
No influence of obesity on mid-term clinical, functional, and radiological results after computer-navigated total knee arthroplasty using a gap balancing technique. 61
33717948 2021
34
Metabolism of testosterone during weight loss in men with obesity. 61
33610798 2021
35
Curcumin analogue C66 attenuates obesity-induced renal injury by inhibiting chronic inflammation. 61
33761621 2021
36
SLC6A14 deficiency is linked to obesity, fatty liver, and metabolic syndrome but only under conditions of a high-fat diet. 61
33513428 2021
37
Canine and Feline Obesity Management. 61
33653534 2021
38
Polysaccharide fraction from greens of Raphanus sativus alleviates high fat diet-induced obesity. 61
33268179 2021
39
Sensory cue reactivity: Sensitization in alcohol use disorder and obesity. 61
33587959 2021
40
A systematic review of neural correlates of dysregulated eating associated with obesity risk in youth. 61
33587960 2021
41
Genetic ablation of C-reactive protein gene confers resistance to obesity and insulin resistance in rats. 61
33544171 2021
42
Heterogeneity in insulin-stimulated glucose uptake among different muscle groups in healthy lean people and people with obesity. 61
33511440 2021
43
Effects of obesity and diabesity on heart rhythm in the Zucker rat. 61
33609055 2021
44
A systematic review and thematic synthesis of qualitative studies exploring GPs' and nurses' perspectives on discussing weight with patients with overweight and obesity in primary care. 61
33283435 2021
45
Demographic, Pregnancy-Related, and Health-Related Factors in Association with Changes in Sleep Among Pregnant Women with Overweight or Obesity. 61
32378048 2021
46
Exercise training decreases whole-body and tissue iron storage in adults with obesity. 61
33559926 2021
47
Pilot Evaluation of a Multidisciplinary Strategy for Laparoscopic Sleeve Gastrectomy in Adolescents and Young Adults with Obesity and Intellectual Disabilities. 61
33797732 2021
48
Pathways to Severe COVID-19 for People with Obesity. 61
33270351 2021
49
Full characterisation of knee extensors' function in ageing: effect of sex and obesity. 61
33526852 2021
50
The relationships between prolonged sedentary time, physical activity, cognitive control, and P3 in adults with overweight and obesity. 61
33526853 2021

Variations for Body Mass Index Quantitative Trait Locus 12

ClinVar genetic disease variations for Body Mass Index Quantitative Trait Locus 12:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 PCSK1 , LOC101929710 NM_000439.5(PCSK1):c.661A>G (p.Asn221Asp) SNV risk factor 14040 rs6232 GRCh37: 5:95751785-95751785
GRCh38: 5:96416081-96416081

Expression for Body Mass Index Quantitative Trait Locus 12

Search GEO for disease gene expression data for Body Mass Index Quantitative Trait Locus 12.

Pathways for Body Mass Index Quantitative Trait Locus 12

GO Terms for Body Mass Index Quantitative Trait Locus 12

Sources for Body Mass Index Quantitative Trait Locus 12

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....